VIROGIN AIMS TO BE A GLOBAL, BEST-IN-CLASS ONCOLYTIC VIRUS COMPANY THAT CREATES IMPACTFUL DRUGS FOR PATIENTS OF THE HIGHEST MEDICAL NEED.


OUR MISSION IS TO DEVELOP NEXT GENERATION ONCOLYTIC VIROTHERAPIES TO ENHANCE THE SYSTEMIC ANTITUMOR IMMUNITY.


Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression.

Learn About Our Technology

Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies for relapsed/refractory cancers to market.

Meet Our Leadership Team

LATEST NEWS